AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9466469
Drug: Allopurinol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (300 mg orally, 12 and 2 hours before ischemia)
Trial: 9466469
Drug: Indomethacin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (50 mg orally, 2 hours before ischemia)
Trial: 2649141
Drug: Mild induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild induction and intensive consolidation therapy
Trial: 2649141
Drug: Mild post
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild post consolidation treatment
Trial: 2649141
Drug: CNS prophylaxis
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNS prophylaxis with intrathecal chemotherapy and intermediate dose i.v. methotrexate (MTX) and cytosine arabinoside (ARA-C)
Trial: 333515
Drug: Oral prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prostaglandin E2 (10 tablets given on an hourly regime)
Trial: 31067324
Drug: QH treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QH treatments in specialist orthodontic clinics (QHS)
Trial: 31067324
Drug: QH treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QH treatments in general dentistry (QHG)
Trial: 31067324
Drug: EP treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP treatments in specialist orthodontic clinics (EPS)
Trial: 31067324
Drug: EP treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP treatments in general dentistry (EPG)
Trial: 27740929
Drug: 11.25- or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11.25- or 30-mg 3-month leuprolide acetate (LA)
Trial: 27740929
Drug: 3-month leuprolide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-month leuprolide acetate treatments
Trial: 27740929
Drug: Basal LH
RxNorm normalized name: LH-708
DrugBank: LH-708 (DB17636)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal LH < 0.60 IU/L
Trial: 19327317
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy (group 2)
Trial: 22584353
Drug: Valacyclovir (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir (2 g q.i.d.)
Trial: 17973956
Drug: Valganciclovir (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valganciclovir (900 mg b.i.d. for a minimum of 14 days)
Trial: 12965978
Drug: Intravenous omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous omeprazole infusion plus endoscopic therapy
Trial: 12965978
Drug: Intravenous omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous omeprazole infusion alone
Trial: 2140382
Drug: Paroxetine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (30 mg/day)
Trial: 2198001
Drug: Breast conservation
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast conservation therapy
Trial: 3887560
Drug: Cefadroxil 1
RxNorm normalized name: CEFADROXIL 1GM TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefadroxil 1 g once daily for 3 days
Trial: 3887560
Drug: Cefadroxil 1
RxNorm normalized name: CEFADROXIL 1GM TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefadroxil 1 g once daily for 7 days
Trial: 3887560
Drug: Amoxycillin 375
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 375 mg t.i.d. for 7 days
Trial: 28668204
Drug: Cisplatin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (75 mg/m2, day 1) and Pemetrexed (500 mg/m2, day 1)
Trial: 28668204
Drug: Cisplatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (80 mg/m2, day 1) and Vinorelbine (25 mg/m2, days 1 and 8)
Trial: 22706833
Drug: Telephone-administered cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-administered cognitive behavioral therapy (T-CBT)
Trial: 24447003
Drug: Face-to-face cognitive
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face cognitive behavioral therapy (FtF-CBT)
Trial: 18616811
Drug: Single-dose pegfilgrastim
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single-dose pegfilgrastim 6 mg
Trial: 18616811
Drug: Daily filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily filgrastim 5 mug/kg
Trial: 15960931
Drug: Samarium-153 (Quadramet)
RxNorm normalized name: Samarium 153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Samarium-153 (Quadramet) therapy
Trial: 12610039
Drug: Acute administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute administration of GLP-1
Trial: 2066762
Drug: Carboplatin 200
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin 200 mg/mq, doxorubicin 45 mg/mq, and cyclophosphamide 600 mg/mq (CAC)
Trial: 2066762
Drug: Cisplatin 50
RxNorm normalized name: cisplatin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 50 mg/mq, doxorubicin 45 mg/mq, and cyclophosphamide 600 mg/mq (PAC)
Trial: 31922425
Drug: Second-line therapies
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line therapies
Trial: 26840067
Drug: Food Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Food Insulin Demand (FID) counting
Trial: 26840067
Drug: Carbohydrate Counting
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate Counting (CC)
Trial: 15798683
Drug: CRN (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRN (no root canal treatment, restored with a crown)
Trial: 9498640
Drug: [N(ε)‐palmitoyl Lys
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [N(ε)‐palmitoyl Lys (B29)] human insulin
Trial: 31828753
Drug: Restrictive intravenous
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive intravenous (IV) fluid therapy
Trial: 31828753
Drug: Standard-care intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-care intravenous (IV) fluid therapy
Trial: 29254987
Drug: DPP-4 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DPP-4 inhibitors (DPP‐4is)
Trial: 27373605
Drug: Concentrate formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrate formulation
Trial: 25287144
Drug: Serelaxin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serelaxin (30 µg/kg per day)
Trial: 21659904
Drug: Nonalcoholic beer
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonalcoholic beer (NAB) 1-1.5 L · d(‐1) for 3 weeks before and 2 weeks after the marathon
Trial: 9210061
Drug: All-trans-retinoic acid
RxNorm normalized name: all-trans-Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All-trans-retinoic acid (tretinoin) at 120 or 150 mg/m2/day for 3 weeks followed by 1 week of rest, given as a single agent.
Trial: 27221567
Drug: PM2.5 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PM2.5 (150 μg/m(3))
Trial: 27221567
Drug: Ozone (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone (240 μg/m(3))
Trial: 24366937
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg orally daily for 2 years
Trial: 17090282
Drug: Tegaserod 2
RxNorm normalized name: tegaserod 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod 2 mg b.i.d.
Trial: 12839848
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy with FLAC/granulocyte-colony-stimulating factor
Trial: 10663415
Drug: bupropion 300
RxNorm normalized name: buPROPion 300 mg/24 hours oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupropion 300 mg/day
Trial: 10663415
Drug: bupropion 150
RxNorm normalized name: BUPROPION 150MG (SMK-C) 12HR SA TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupropion 150 mg/day
Trial: 29383896
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment + acupuncture therapy (observation group)
Trial: 27798895
Drug: Oral tegafur/gimeracil/oteracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tegafur/gimeracil/oteracil (S‐1)
Trial: 20658835
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group writing about facts of diagnosis and treatment (CTL; n = 31)
Trial: 16022024
Drug: Oral-B
RxNorm normalized name: Oral-B Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-B
Trial: 11805503
Drug: BioMask treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BioMask treatment with excimer laser phototherapeutic keratectomy (PTK)
Trial: 9916956
Drug: Depot leuprolide
RxNorm normalized name: leuprolide acetate Injectable Suspension [Lupron Depot]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depot leuprolide (3.75 mg/mo)
Trial: 7583865
Drug: Perfume inhalation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perfume inhalation from magazine scent strips
Trial: 2305013
Drug: Scopolamine 0.22
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine 0.22 mg/70 kg
Trial: 2305013
Drug: Scopolamine 0.43
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine 0.43 mg/70 kg
Trial: 2305013
Drug: Scopolamine 0.65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine 0.65 mg/70 kg
Trial: 348535
Drug: Mianserin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin (10 mg t.d.s. for the first week, increasing to 20 mg t.d.s. for the subsequent three weeks)
Trial: 348535
Drug: Amitriptyline (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (25 mg t.d.s. for the first week, increasing to 50 mg t.d.s. for the subsequent three weeks)
Trial: 28291862
Drug: Splinted prostheses
RxNorm normalized name: brilliant green
DrugBank: Brilliant green cation (DB11279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Splinted prostheses with short implants (short group SP)
Trial: 28291862
Drug: Nonsplinted prostheses
RxNorm normalized name: LARYNGEAL PROSTHESIS,PROVOX #8273
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsplinted prostheses with regular implants (regular group NSP)
Trial: 28291862
Drug: Splinted prostheses
RxNorm normalized name: brilliant green
DrugBank: Brilliant green cation (DB11279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Splinted prostheses with regular implants (regular group SP)
Trial: 28291862
Drug: Nonsplinted prostheses
RxNorm normalized name: LARYNGEAL PROSTHESIS,PROVOX #8273
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsplinted prostheses with short implants (short group NSP)
Trial: 20497432
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (group I)
Trial: 20497432
Drug: Peribulbar triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peribulbar triamcinolone orbital injection (group II)
Trial: 16324269
Drug: Capsaicin inhalation
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsaicin inhalation cough challenge test by dosimeter method
Trial: 12826636
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of oral prednisone once daily for 10 days
Trial: 8651227
Drug: multiple vitamin/mineral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple vitamin/mineral supplement
Trial: 2052468
Drug: Volmax 8
RxNorm normalized name: Volmax 8mg Extended-Release Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volmax 8 mg orally every 12 hours for 3 days
Trial: 2052468
Drug: Proventil Repetabs
RxNorm normalized name: Proventil Repetabs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proventil Repetabs 8 mg orally every 12 hours for 3 days
Trial: 28091350
Drug: High-flavanone (HF;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flavanone (HF; 70.5 mg) drink
Trial: 23713782
Drug: KOH 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KOH 5% solution
Trial: 23713782
Drug: KOH 2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KOH 2.5% solution
Trial: 23801093
Drug: Commercial immuno-enhancing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial immuno-enhancing supplement 5 days preoperatively
Trial: 28848225
Drug: No supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No supplements (Control)
Trial: 14998080
Drug: Intravenous moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous moxifloxacin 400 mg once-daily
Trial: 14998080
Drug: Oral moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral moxifloxacin 400 mg once-daily
Trial: 29907335
Drug: Mindfulness-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based intervention (weekly sessions for 8 weeks)
Trial: 22876442
Drug: Basic weight-reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic weight-reduction treatment (Control group)
Trial: 10793433
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT), n = 25
Trial: 10793433
Drug: No Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Therapy (NT), n = 24
Trial: 8656502
Drug: Lamivudine 150
RxNorm normalized name: lamivudine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 150 mg every 12 hours plus zidovudine
Trial: 8656502
Drug: Lamivudine 300
RxNorm normalized name: lamivudine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 300 mg every 12 hours plus zidovudine
Trial: 17377691
Drug: 0.3% Triclosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% Triclosan varnish applied twice a year (every half year) for one year.
Trial: 15704508
Drug: 12 additional
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 additional therapy sessions (over four weeks) comprising exercises aimed at improving lateral weight transference in sitting delivered by trained physiotherapy assistants
Trial: 11897208
Drug: niacin/lovastatin 500/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: niacin/lovastatin 500/10 mg
Trial: 11897208
Drug: niacin/lovastatin 1,000/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: niacin/lovastatin 1,000/20 mg
Trial: 11897208
Drug: niacin/lovastatin 1,500/30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: niacin/lovastatin 1,500/30 mg
Trial: 11897208
Drug: niacin/lovastatin 2,000/40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: niacin/lovastatin 2,000/40 mg
Trial: 9854276
Drug: Guided imagery
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided imagery therapy for 6 weeks
Trial: 9854276
Drug: Guided imagery
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided imagery therapy
Trial: 8548055
Drug: High-dose progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose progesterone (0.714 mg.kg‐1.h‐1 for 60 min followed by 0.45 mg.kg‐1.h‐1 over 315 min)
Trial: 8548055
Drug: High-dose progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose progesterone
Trial: 28118454
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment during washout
Trial: 26414234
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (CES device turned on and off)
Trial: 23472927
Drug: Single-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose intravenous cephalothin
Trial: 23472927
Drug: Single-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose intravenous cephalothin plus oral amoxicillin/clavulanate for 7 days
Trial: 19183157
Drug: Dexlansoprazole MR
RxNorm normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole MR 90 mg in moderate-to-severe EO
Trial: 9542607
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with birch-pollen extract
Trial: 3349417
Drug: Protein A
RxNorm normalized name: Protein antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein A treatment (Prosorba column containing 50 or 200 mg protein A, administered 12 times either once per week or three times per week)
Trial: 3349417
Drug: Protein A
RxNorm normalized name: Protein antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein A treatment (Prosorba column)
Trial: 28882371
Drug: Dexmedetomidine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.1 mg kg−1) and midazolam (1.0 mg kg−1)
Trial: 28882371
Drug: Alfaxalone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfaxalone (15 mg kg−1) and midazolam (1.0 mg kg−1)
Trial: 23873559
Drug: Added P
RxNorm normalized name: P & S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Added P from KH2PO4 at levels of 0, 0.7, 1.4, or 2.1 g/kg of diet
Trial: 23873559
Drug: Diet with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet with 5 g of highly soluble calcium (HSC)
Trial: 15582348
Drug: Self-treatment program
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-treatment program with additional information on recognizing prodromal signs and doubling inhaled corticosteroids (ICS) during one week
Trial: 15582348
Drug: Structured information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured information on asthma, symptoms, and medication
Trial: 1387351
Drug: Intravenous sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sufentanil (150 micrograms)
Trial: 4076202
Drug: Metoprolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (10 mg)
Trial: 3793280
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Nisoldipine + Metoprolol)
Trial: 3793280
Drug: Order of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Order of administration (Nisoldipine added to Metoprolol)
Trial: 29359848
Drug: Weight-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-based treatment (0.3 g glucose/kg body-weight)
Trial: 29359848
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose of 12 g glucose
Trial: 29359848
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose of 30 g glucose
Trial: 17462639
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist trigger after cotreatment with GnRH antagonist
Trial: 17462639
Drug: hCG trigger
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG trigger after dual pituitary suppression with a GnRH agonist
Trial: 15982504
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin C administration
Trial: 11865815
Drug: TMTX/5-FU/LV (TMTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMTX/5-FU/LV (TMTX 110 mg/m2 i.v. followed by LV 200 mg/m2/5-FU 500 mg/m2 plus oral LV rescue)
Trial: 11865815
Drug: 5-FU/LV (5-FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU/LV (5-FU 600 mg/m2 in Europe and 500 mg/m2 in USA)
Trial: 8938912
Drug: Haloperidol treatment
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol treatment
Trial: 2861844
Drug: Terfenadine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine and Cimetidine (in combination)
Trial: 30207844
Drug: Continuous diffusion
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous diffusion of oxygen (CDO) therapy